ISSN: 2161-0681

Журнал клинической и экспериментальной патологии

Открытый доступ

Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.

 

Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей

Индексировано в
  • Индекс Коперника
  • Google Scholar
  • Шерпа Ромео
  • Открыть J-ворота
  • Генамика ЖурналSeek
  • ЖурналТОС
  • Справочник периодических изданий Ульриха
  • РефСик
  • Университет Хамдарда
  • ЭБСКО, Аризона
  • OCLC- WorldCat
  • Публикации
  • Женевский фонд медицинского образования и исследований
  • Евро Паб
  • ICMJE
Поделиться этой страницей

Абстрактный

Nomogram Based Survival Predictions of Patients with Soft Tissue Cancer Including Heart in the United States

Roungu Ahmmad

Introduction: This study aimed to assess the effects of cancer treatment on sarcoma types and to predict overall survival probabilities using nomograms.

Methods: This study uses the SEER-18 database, version 2020, sponsored by the National Cancer Institute (NCI). The study cohort included participants diagnosed between 2000 and 2018 with soft tissue cancers including heart. A multivariable stratified Cox proportional hazards model was applied to predict mortality rate and nomograms were used to predict overall survival probability.

Results: The median survival time for 24,849 study participants was 48 months (IQR: 19-102) with Spindle cell Sarcoma (ScS) having a shorter median survival time compared with Liposarcoma (LiS). A significant number of Soft Tissue Sarcoma (STS) patients had surgery, where surgery on ScS improved survival by 75% (HR: 0.25, 95% CI: 0.19-0.32, p<0.001) and those who received radiation had a 26% improvement (HR: 0.74, 95% CI: 0.61-0.89, p=0.001). Furthermore, chemotherapy on GcS resulted in a 40% reduction in mortality for patients compared to those who did not receive chemotherapy (HR: 0.60, 95% CI: 0.45-0.80, p<0.001). Based on nomogram, after two, five and ten years, a patient who received surgery on their primary sites would have a survival rate of approximately 90%. In contrast, a patient who did not receive surgery on their primary sites would only live for 20% or less. Patients with MyS have a 90% chance of surviving for 5 and 10 years after surgical intervention, but only 22% and 10% without surgery.

Conclusion: Based on the results of this study, surgical and radiation intervention was associated with improved survival in patients with STS, while chemotherapy and primary systemic therapy had contradictory effects.

Отказ от ответственности: Этот реферат был переведен с помощью инструментов искусственного интеллекта и еще не прошел проверку или верификацию.